Table 2.
Adverse events
| All Subjects (n=12) | |
|---|---|
| Number of adverse events reported | 162 |
| Number of subjects with adverse events | 12 (100 %) |
| Number of serious adverse events | 2 |
| Number of serious adverse events related to rituximab1 | 1 |
| Number of subjects with serious adverse events | 2 (16.7%) |
| Number of adverse events by severity | |
| Mild (grade 1) | 138 (85.2%) |
| Moderate (grade 2) | 20 (12.3%) |
| Severe (grade 3) | 4 (2.5%) |
| Life-threatening (grade 4) | 0 |
| Fatal (grade 5) | 0 |
| Number of subjects with adverse events by severity | |
| Mild (grade 1) | 5 (41.7%) |
| Moderate (grade 2) | 5 (41.7%) |
| Severe (grade 3) | 2 (16.7%) |
1
Subject diagnosed with squamous carcinoma of the skin 301 days after rituximab therapy